Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
This year, we got exciting new data about an HIV drug in development that may become an every-six-month, self-administered antiretroviral injection. But we learned about it via press release, rather than carefully presented research.
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
The international news story that broke at AIDS 2020, explained by the lead researcher.
This Champion of Community’s Role in Clinical Trials Reflects on 40 Years of Fighting Medical Mistrust And Research Neglect
Wakefield retires from the HIV Vaccine Trials Network after 20 years of service.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
Because the public is getting so many mixed messages, it’s our responsibility to provide clarity and moderate optimism.
Whether HIV or COVID-19, Pregnant or Lactating Cisgender Women Need to Be Included in Clinical Trials for Therapies
Dr. Shahin Lockman says to not include women in trials is unethical.